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ABSTRACT 
Secondary acute myeloid leukemia (s-AML) refers to patients with either therapy-related 
AML (t-AML), that is, AML after treatment with chemo- and/or radiation for a prior disease, 
or AML progressing from an antecedent hematologic disorder (AHD-AML), typically a 
myelodysplastic syndrome (MDS) or a myeloproliferative neoplasm. Patients with s-AML 
present with higher rates of adverse cytogenetic aberrations and higher frequencies of adverse 
mutations and, subsequently, respond worse to therapy, and have poorer outcome compared 
to de novo AML. To identify clinical and molecular factors that may improve prognostication 
is therefore of importance to guide clinical decision-making. 
The general aim of this thesis was to broaden the real-world knowledge of s-AML, regarding 
disease properties and outcome, using population-based registries, and additionally to 
investigate the importance of mutations in the transformation from MDS to AML. The 
research papers presented herein cover mutational screening in MDS and s-AML (study I), 
general characteristics and outcome of s-AML (study II), the role of allogeneic 
hematopoietic cell transplantation (HCT) in patients with s-AML (study III), and the 
epidemiology and treatment outcome specifically for t-AML (study IV). 
In study I, high-throughput methods were used to find mutations in 22 genes in 100 MDS 
and 92 AML patients. The AML cohort consisted of t-AML, AHD-AML and AML with 
MDS-like cytogenetics. In AML, mutations were most commonly seen in oncogenes and cell 
signaling genes, and in MDS in splicing factor genes and epigenetic regulators. A key finding 
was the overrepresentation of mutated U2AF1 in cases with MDS progressing to AML. 
Furthermore, in addition to established risk scores, mutational status improved 
prognostication. 
In study II we used the Swedish AML registry (SAMLR) to characterize s-AML in a 
population-based setting. Of the 3263 AML patients included, 19% were AHD-AML and 8% 
t-AML. Differences between the subtypes were found in age, gender distribution and 
cytogenetic risk. Compared to de novo AML, complete remission rates were lower in s-AML, 
but early death rates were similar. In multivariable analysis, both t-AML and AHD-AML 
emerged as independent prognostic factors, with a more pronounced negative impact in 
younger age groups. 
HCT is a potentially curable consolidation treatment in eligible patients. In study III, data on 
3337 intensively treated patients in SAMLR were combined with data from the Swedish 
Cancer Registry (SCR) and the Swedish transplantations centers to investigate the role of 
HCT in s-AML. HCT in first remission was superior to consolidation treatment with 
chemotherapy only. Long-term survivors with s-AML were rare without HCT. 
In study IV we studied 686 patients with t-AML in detail using SAMLR, SCR and the 
Swedish Rheumatology Quality Register. We found an increasing incidence of t-AML over 
time, and an increasing proportion with t-AML of AML in total. Survival was overall dismal, 
but comparable to de novo AML in patients with favorable cytogenetic risk and in patients 
with mutated NPM1 in combination with absence of FLT3-ITD. 
In conclusion, secondary AML is a highly heterogeneous disease with a particularly poor 
outcome. However, the clinical and genetic differences within the disease enable risk 
stratification of patients and may thus aid in treatment recommendations. 
  
  
POPULÄRVETENSKAPLIG SAMMANFATTNING 
Akut myeloisk leukemi, AML, är en cancersjukdom i de blodbildande cellerna i benmärgen. 
Sjukdomen beror på förvärvade molekylära avvikelser i blodets stamceller i form mutationer, 
kromosomrubbningar och epigenetiska förändringar. AML är den vanligaste akuta leukemin 
hos vuxna och drabbar framförallt äldre. Ca 350 individer insjuknar i AML årligen i Sverige. 
Prognosen är dyster med en 5-årsöverlevnad på endast 20%. Behandlingen består av 
intensiva cytostatikakurer och för långtidsöverlevnad och bot krävs oftast allogen 
blodstamcellstransplantation, vilket i regel är förbehållet yngre patienter utan större 
samsjuklighet. 
Ungefär en fjärdedel av sjukdomsfallen är av typen sekundär-AML. Då har det antingen skett 
en övergång från en annan blodcancer, så kallad AHD-AML (AML with an antecedent 
hematologic disorder). Eller så har patienten tidigare behandlats med cytostatika eller 
strålning för en annan sjukdom, oftast cancer, och har då terapirelaterad AML (therapy-
related AML). Båda typerna av sekundär-AML har ännu sämre prognos än de novo-AML, 
som nyinsjuknadende i AML kallas.  
Den dystra prognosen belyser ett ouppfyllt behov i behandlingen av patienter med sekundär-
AML. Målet med denna avhandling var att fördjupa karaktäriseringen av sekundär-AML, 
framförallt för att öka förståelsen av de faktorer som påverkar behandlingsutfallet. Syftet är 
att i förlängningen förbättra möjligheten att välja optimal behandling för enskilda individer. 
Avhandlingsarbetet har resulterat i fyra studier som sammanfattas nedan. 
I studie I användes så kallad next-generation-sekvensering för att upptäcka mutationer i 22 
gener i 92 patienter med sekundär-AML och 100 patienter med myelodysplastiskt syndrom 
(MDS, en besläktad blodcancer som kan övergå i AML). Till stor del var det olika gener som 
var muterade i AML och MDS, vilket återspeglar den underliggande biologiska funktionen 
generna har i respektive sjukdom. Ett huvudfynd var associationen mellan sjukdomsprogress 
från MDS till AML och samtidig förekomst av en muterad gen kallad U2AF1. 
I studie II karaktäriserades sekundär-AML med hjälp av data från svenska AML-registret. 
Bland totalt 3263 patienter hade 8% terapirelaterad AML och 19% AHD-AML. Sekundär-
AML skilde sig från de novo AML framförallt avseende genetisk riskprofil. De fick i mindre 
utsträckning intensiv cytostatikabehandling än de novo-patienter och de med sekundär-AML 
svarade sämre på behandling. Att ha sekundär-AML visade sig ha negativ påverkan på 
överlevnad oberoende av andra etablerade riskfaktorer. Den prognostiska betydelsen av 
sekundär-AML var tydligare hos yngre än hos äldre patienter.  
Även i studie III användes svenska AML-registret, där tillsammans med data från 
Socialstyrelsens cancerregister och de svenska transplantationscentren. Huvudsyftet var att 
undersöka hur allogen blodstamscellstransplantation används och påverkar utfallet vid 
sekundär-AML. Det visade sig att ytterst få patienter med sekundär-AML blev 
långtidsöverlevare utan transplantation. Att genomgå transplantation i s.k. första remission 
var överlägset behandling med enbart cytostatika. 
Studie IV fokuserade på patienter med terapirelaterad AML. Data från svenska AML-
registret på 686 patienter kombinerades med data från Socialstyrelsens cancerregister och 
Svensk Reumatologis Kvalitetsregister. Huvudsakliga fynd var att incidensen av t-AML 
tydligt ökar över tid och att andelen terapirelaterad AML av AML-fallen totalt blev allt större. 
Överlevnaden vid terapirelaterad AML var generellt mycket dyster, men i vissa genetiska 
undergrupper var den bättre och jämförbar med patienter med motsvarande genetisk 
riskprofil som nyinsjuknat i AML. 
Sammanfattningsvis är sekundär-AML en ovanlig sjukdom som är mycket svårbehandlad. 
Nya läkemedel kommer att krävas för att förbättra överlevnaden, men förhoppningsvis 
kommer sådana att utvecklas hand i hand med den ökade förståelsen av sjukdomsbiologin. 
Behandlingen av AML har i stort sett varit oförändrad i årtionden, men nyligen har läkemedel 
som bl.a. utnyttjar specifika genetiska avvikelser introducerats. Inom andra cancerformer har 
immun- och cellterapi fått stort genomslag och dessa är potentiellt användbara även mot 
AML. För gruppen med sekundär-AML är det därför av stor betydelse att sjukdomshistorik, 
hög ålder och samsjuklighet inte utgör hinder för deltagande i kommande läkemedelsstudier. 
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1 INTRODUCTION 
Acute myeloid leukemia is the most common type of acute leukemia in adults with more than 
300 new cases every year in Sweden [1]. The disease is characterized by high mortality and a 
low cure rate with a median survival of less than 7 months [1]. The molecular basis of AML 
is highly heterogeneous, with multiple recurrent genetic alterations such as specific 
chromosomal aberrations, gene mutations and DNA methylation patterns [2, 3]. 
Accumulations of these alterations lead to block in the differentiation of myeloid stem and 
progenitor cells, and to clonal proliferation of leukemic cells in the bone marrow. Despite 
recent advances in the knowledge about the molecular pathogenesis in AML, the 
leukemogenic process remains largely unclear. 
Until recently, the treatment of AML had basically not changed for almost 50 years [4], with 
a remaining poor prognosis . However, during the last few years, concurrent to the growing 
understanding of the genetic basis of AML, a number of new drugs complementing the 
standard therapy have shown promising results in clinical trials. This is a hopeful 
advancement, but it remains to be seen how big the improvement will be in clinical reality. 
The majority of patients present with de novo AML, without any preceding hematologic 
disease or other cancer. However, 20% have an antecedent hematologic disorder (AHD-
AML), typically a disease progression from myelodysplastic syndromes (MDS), 
myeloproliferative neoplasms (MPN) or chronic myelomonocytic leukemia (CMML) [5]. In 
yet another 5-10%, the patients have therapy-related AML (t-AML) [5-7], with a history of 
cytotoxic therapy or radiation therapy for a prior malignant or non-malignant disease. 
Together these two entities, AHD-AML and t-AML, make up a loosely defined group called 
secondary AML (s-AML). 
These definitions are not part of the World Health Organization (WHO) classification 
system, and the usage varies in the literature. Some authors use s-AML to describe both t-
AML and AHD-AML, while others use it only referring to AML with a preceding 
hematological disease. The WHO defines the disease entity therapy-related myeloid 
neoplasms (t-MNs) as myeloid neoplasms secondary to cytotoxic treatment, in which t-AML 
is categorized along with therapy-related MDS and therapy-related MDS/MPN [8].  
Secondary AML frequently harbors unfavorable genetic aberrations, and the outcome is 
poorer than in de novo AML, both in response to chemotherapy and survival [5, 9]. 
Historically, these patients often escape inclusion in clinical trials [10], and are thus less 
thoroughly studied than those with de novo AML. 
1.1 EPIDEMIOLOGY 
The incidence rate of AML in Europe has been reported to 3.6 cases per 100,000 inhabitants 
per year during 2000-2002 [11]. Recent U.S. data from 2012-2016 shows a rate of 4.3 per 
100,000 [12]. Worldwide, the incidence is elevated in highly developed areas, with the 
highest rates in Australia, USA and parts of Europe [13]. Prevalence is less known, however 
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in Sweden, during a snapshot in 2014, the overall prevalence of AML was 13.7 per 100,000, 
while the prevalence of patients surviving three or more years was 9.0 per 100,000 [14]. 
Although AML occurs in all ages it is considerably more common in the elderly, with a 
median age at diagnosis of 71 years [1]. Correspondingly, the incidence rate steadily 
increases by age to a peak at 80-85 years, where the incidence rate is >15 cases per 100.000 
compared to <5 in the age <60. There is no gender difference in the total number diagnosed 
each year, but as a consequence of the age structure in western countries, AML is more 
common in males than females above the age of 70 [1, 11]. 
S-AML accounts for 20-25% of all AML cases, whereof AHD-AML constitutes about two 
thirds and t-AML one third of s-AML in total [5-7]. The median age at diagnosis is higher in 
AHD-AML than in de novo and t-AML [5]. Females are predominant in t-AML, since breast 
cancer and gynecological cancers are more common as primary malignancies than male 
cancers [6, 15], and males are more common in AHD-AML, reflecting the male 
predominance in MDS [16].  
1.2 CLINICAL PRESENTATION 
Different manifestations of bone marrow failure related to blast infiltration lead to the initial 
symptoms in AML. These are fatigue caused by anemia, bleeding due to thrombocytopenia, 
and infections explained by neutropenia. Patients may present debilitated with severe 
infections or bleeding, but more commonly with mild symptoms, and cases are sometimes 
discovered unexpectedly through routine blood tests. In patients with MDS or MPN, a 
gradual developing anemia or other alterations in the peripheral blood counts could be signs 
of progress to s-AML. 
1.3 DIAGNOSIS 
The basis of diagnosis is a bone marrow aspirate with > 20% myeloid blasts (myeloblasts, 
monoblasts or megakaryoblasts), with the exception of the cytogenetic abnormalities t(8;21), 
inv(16) and t(15:17), which all qualify as AML independent of blast count [3]. Consequently, 
cytogenetic analysis is performed to aid classification and prognostication. Flow cytometry is 
run to ensure correct diagnosis, and to find an immunophenotypic profile that can be used 
during treatment to measure residual disease [17]. Fluorescence in situ hybridization (FISH) 
and reverse transcriptase polymerase chain reaction (RT-PCR) are rapid molecular methods 
commonly used to find specific chromosomal rearrangements of importance in certain 
clinical situations [3]. In addition, screening for mutations using NGS-based gene panels adds 
prognostic information [18]. 
  
  3 
1.4 CLASSIFICATION 
The current WHO-classification (2016 revision) divides AML into subgroups based on 
recurrent cytogenetic and mutational aberrations, presence of morphologic dysplasia, history 
of prior MDS, or history of prior cytotoxic therapy [8, 19]:  
• AML with recurrent genetic abnormalities includes a number of cytogenetic and 
mutational aberrations that have proven to be of clinical relevance. For instance, the 
favorable risk core binding factor (CBF) leukemias with t(8;21), inv(16) and t(16;16) 
along with the PML-RARA fusion defining favorable risk acute promyelocytic 
leukemia (APL) belong in this group, as well as adverse risk aberrations such as 
t(9;11) and inv(3). Mutations in NPM1, RUNX1 (provisionally) and biallelic 
mutations in CEBPA also define disease entities in the group with recurrent 
aberrations. 
 
• AML with myelodysplasia-related changes (AML-MRC) encompasses AML either 
progressed from MDS or MDS/MPN, or cases with morhological dysplasia in >50% 
of cells in at least 2 cell lines, along with cases with certain MDS-related cytogenetic 
abnormalities (Table I).  
 
• Therapy-related myeloid neoplasms, as already described, include t-AML, t-MDS and 
t-MDS/MPN following cytotoxic therapy, and should be seen as a clinical syndrome 
defined by iatrogenic mutagenic exposure. 
 
• AML, not otherwise specified, is used when the other classification criteria are not 
met. 
 
• The WHO-classification also includes the two AML manifestations myeloid sarcoma 
and myeloid proliferations of Downs syndrome as distinct subgroups 
 
Thus, proper classification requires cooperation between hematopathologists, geneticists and 
clinicians. Accordingly, while there is no specific WHO category for s-AML, patients with s-
AML fall into any of the three WHO subcategories t-MN, AML-MRC or AML with 
recurrent genetic abnormalities. 
Related to the classification of AML, there is a special section on myeloid neoplasms, 
including MDS and AML, with germ line predisposition in the 2016 WHO revision, due to 
the raising awareness that a subset of cases are not sporadic but inherited, which is highly 
important for patient management and for informing the affected families [19, 20]. 
  
 4 
Table I. List of the MDS-related cytogenetic abnormalities. 
Complex karyotype (>= 3 abnormalities) 
Unbalanced abnormalities 
      -7/del(7q) 
      del(5q)/t(5q) 
      i(17q)/t(17p) 
      -13/del(13q) 
      del(11q) 
      del(12p)/t(12p) 
      idic(X)(q13) 
Balanced abnormalities 
      t(11;16)(q23.3;p13.3)  
      t(3;21)(q26.2;q22.1) 
      t(1;3)(p36.3;q21.2) 
      t(2;11)(p21;q23.3) 
      t(5;12)(q32;p13.2) 
      t(5;7)(q32;q11.2) 
      t(5;17)(q32;p13.2) 
      t(5;10)(q32;q21.2) 
      t(3;5)(q25.3;q35.1) 
Reprinted with permission from IARC/WHO: WHO Classification of Tumours of Haematopoietic and 
Lymphoid Tissues, Revised 4th Edition, Vol 2, SH. Swerdlow et al, copyright 2017. 
 
1.5 PROGNOSIS 
Multiple factors contribute to the outcome of AML and the genetic properties inherent in the 
disease have the most impact. However, prognosis also depends on patient-related factors 
such as age, fitness and comorbidities. Additional post-treatment prognostication is enabled 
by assessing treatment response and measurable residual disease.  
1.5.1 Genetic risk classification 
Cytogenetic evaluation has traditionally been, and still is, the basis of prognosis and treatment 
decisions in AML [3]. Large studies have shown that cytogenetic aberrations stratify AML by 
overall survival, and three distinct prognostic groups are used clinically: favorable, 
intermediate and adverse cytogenetic risk [21]. The value of gene mutations to further refine 
the classification has become evident, and current 2017 European LeukemiaNet (ELN) 
classification requires the mutational status of NPM1, FLT3-ITD, CEBPA, RUNX1, ASXL1 
and TP53 [3]. 
Table II shows a simplified summarization of the genetic risk stratification according to ELN. 
Risk classification is mainly used as a tool to identify individuals with a low risk of long-term 
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survival after standard treatment, who would benefit from allogeneic stem cell 
transplantation. Patients in the intermediate and adverse risk groups have high and very high 
risk of relapse, respectively, and should be considered for HCT if otherwise eligible [22, 23]. 
 
Table II. Genetic risk stratification according to ELN 2017 (footnotes omitted). 
Risk Genetic abnormality 
Favorable t(8;21)(q22;q22.1); RUNX1-RUNX1T1 
inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH1 
Mutated NPM1 without FLT3-ITD or with FLT3-ITDlow 
Biallelic mutated CEBPA 
Intermediate Mutated NPM1 and FLT3-ITDhigh 
Wild-type NPM1 without FLT3-ITD or with FLT3-ITDlow 
    (without adverse-risk genetic lesions) 
t(9;11)(p21.3;q23.3); MLLT3-KMT2A 
Cytogenetic abnormalities not classified as favorable or adverse 
Adverse t(6;9)(p23;q34.1); DEK-NUP214 
t(v;11q23.3); KMT2A rearranged 
t(9;22)(q34.1;q11.2); BCR-ABL1 
inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2,MECOM(EVI1) 
-5 or del(5q); 27; 217/abn(17p) 
Complex karyotype, monosomal karyotype 
Wild-type NPM1 and FLT3-ITDhigh 
Mutated RUNX1 
Mutated ASXL1 
Mutated TP53 
Reprinted with permission from American Society of Hematology: Blood, Diagnosis and management 
of AML in adults: 2017 ELN recommendations from an international expert panel, H. Döhner et al, 
copyright 2017. 
 
1.5.2 Secondary AML as a prognostic factor 
Secondary AML is a well-known adverse prognostic factor [6, 7, 9]. Patients with t-AML and 
AHD-AML are less responsive to intensive induction treatment, reflected in lower complete 
remission (CR) rates than in de novo AML, and they have shorter overall survival compared 
to novo AML [5, 21, 24]. Whether secondary AML confers a negative impact on outcome 
independently from the karyotype and age has been debated, but at least for cytogenetics 
several studies point in that direction [9, 25, 26]. However, the adverse prognostic impact of 
both t-AML and AHD-AML seems stronger in younger than in elderly patients [5, 6, 27]. In 
t-AML patients, this might be explained by increased mortality in younger due to the 
cumulative toxicity of treatment [6]. 
It is possible to identify subsets within s-AML with particularly dismal outcomes. Among 
patients with AHD-AML, a prior MPN or CMML confers worse outcome than a diagnosis of 
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MDS, regardless of age or cytogenetics [5]. Furthermore, patients with AHD-AML that have 
been treated for their prior MDS, MPN or aplastic anemia (AA) do worse than untreated 
patients, and define a distinct high-risk subgroup of AHD-AML [28]. In t-AML, scoring 
models to enhance risk stratification by integrating factors related to the treatment for the 
primary disease (e.g. type of chemotherapy) have been developed [29]. 
1.5.3 Additional prognostic factors 
Other prognostic parameters are age, performance status, comorbidity, hyperleukocytosis, 
extramedullar manifestations and multilineage dysplasia. 
• Treatment results of older patients are considerable worse than younger. Partly 
explained by a larger proportion of high-risk cytogenetics in the elderly and that a 
preceding diagnosis or phase of MDS is more common at higher age [30, 31]. 
• Poor performance status at the time of diagnosis is strongly associated with poor 
short- and long-term survival [32]. 
• Systematic comorbidity assessment can predict early death and survival after 
induction therapy [33]. 
• Elevated white blood cell counts (WBC), hyperleukocytosis, is seen in 5-10% of 
newly diagnosed patients and is a risk factor for early death by bleeding, 
thromboembolic events and pulmonary or CNS complications [34]. 
• Extramedullary disease is present in more than 20% of patients and is associated with 
shorter OS but lacks independent prognostic value [35]. 
• Multilineage dysplasia confers poor survival but is highly correlated to adverse MDS-
related cytogenetics, and thus has no independent prognostic value [36]. 
1.5.4 Novel prognostic methods 
In recent years the knowledge about the molecular basis of AML has been vastly increased, 
mainly due to the rapid development of sequencing techniques. The findings in disease 
mechanism go hand in hand with new predictive markers. In addition to mutations, profiles of 
gene expression [37, 38], signatures of non-coding RNAs [39, 40] and DNA methylation 
patterns [41, 42] all have proved to add prognostic information. Even though the molecular-
based risk stratification models (for instance combining gene expression profiling with either 
or both cytogenetic and mutational data) may improve established prognostic models, most of 
them are not validated or replicated in larger cohorts [43]. Furthermore, the molecular 
methods required may be expensive or technically challenging. Thus, so far, apart from 
cytogenetics, only mutational profiling has been incorporated in guidelines and clinical 
routine.  
1.6 ETIOLOGY 
The reason why AML occurs de novo is not completely known. The only known lifestyle risk 
factor is smoking. In meta-analysis it has been estimated that smokers have a 40% higher risk 
of AML than non-smokers [44]. Recently it has also been suggested that smoking is 
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associated with genetically high-risk AML and poorer outcome [45].  Prolonged exposure to 
high levels of benzene is also a known causative factor, however the statistical evidence for 
an association between work-related exposure and increased risk is weak, and it is not 
considered a concern in developed countries [46, 47]. 
Among children and young adults there is a considerably elevated risk of AML in a number 
of, mostly very rare, inherited syndromes, e.g. Down's syndrome, Shwachman–Diamond 
syndrome, Fanconi anemia, dyskeratosis congenita and severe congenital neutropenia [48]. 
However due to increased use of diagnostic genome sequencing, genetic predisposition to 
AML and MDS is found in adults well, with our without other clinical signs [49]. Germ line 
predisposition, with mutations in RUNX1, GATA2 and CEBPA among others, is now well 
recognized and incorporated into the WHO classification [50]. In addition, through genome 
wide association studies, there is some evidence suggesting existence of low-penetrance risk 
alleles for AML [51]. 
1.6.1 AML secondary to other myeloid neoplasms 
AHD-AML accounts for the majority patients with s-AML, and the myeloid neoplasms 
preceding AML are MDS (~60%), MPN (~30%) and CMML (~10%) [5]. The progression to 
AML is explained by a gradual clonal evolution and one can argue that the term secondary is 
somewhat misleading since the disease evolvement genetically covers a continuous spectrum 
of conditions [52].  
1.6.1.1 AML progressing from MDS 
The myelodysplastic syndromes are clonal myeloid malignancies characterized by 
morphologic dysplasia in the hematopoiesis and bone marrow failure, resulting in peripheral 
blood cytopenias and risk of AML progression. The incidence is 5 cases per 100,000 per year 
and it is considerably more common in the elderly [53]. MDS is classified into subgroups 
based on degree of dysplasia and blast counts on morphology, ring sideroblast percentages, 
and presence of specific cytogenetic aberrations (e.g. del(5q)). Cytogenetics and clinical 
parameters divide patients into prognostic risk groups using the revised international 
prognostic scoring system (IPSS-R), with a variable risk of disease progression and death 
[54]. The median time to AML transformation varies from only a couple of months to ~10 
years in high and low risk disease respectively. There is a considerable overlap between MDS 
and AML in cytogenetic abnormalities and mutations, particularly in the higher risk groups, 
and incorporation of mutational status enhances the prognostic scoring systems [55-57]. The 
most commonly mutated genes in MDS are TET2, SF3B1, ASXL1, SRSF2, DNMT3A, and 
RUNX1 [55]. During the progression from MDS to AML, either mutations (e.g. in FLT3, 
NRAS, IDH2) or additional chromosome abnormalities, or both, are gained [58, 59]. This 
process can be described as a genetic evolution, where multiple mutational clones evolve 
over time, forming subclones, of which some are selected and persist over time, until 
progression to AML, where an increased number of mutations and enlarged clone sizes are 
seen [59, 60].  
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1.6.1.2 AML progressing from myeloproliferative neoplasms 
The myeloproliferative neoplasms are a group of clonal myeloid diseases characterized by 
proliferation of mature blood cells. In polycythemia vera (PV), there is an excess of red blood 
cells, in essential thrombocytosis (ET) platelets, and in primary myelofibrosis (PMF) bone 
marrow fibrosis [61]. The risk of AML/MDS transformation over a 10-year period is 2-5%, 
5-10% and 8-20% in ET, PV and PMF, respectively [62]. A mutation in JAK2 is seen in the 
majority of the MPN patients, and drives the disease by activating the JAK2-STAT signaling 
pathway. Mutated JAK2 defines PV, whereas mutated CALR or MPL are found in JAK2 
negative ET and PMF. Post MPN-AML is associated with a very poor prognosis with a 
median OS of less than 6 months [63] where mutations in TP53, SRSF2 and TET2 have been 
shown to have an adverse impact on survival [64].   
1.6.1.3 AML progressing from CMML 
CMML belongs in the WHO category myelodysplastic/myeloproliferative neoplasms 
(MDS/MPN) and shares clinical and genetic features with MDS but displays a 
myeloproliferative phenotype [19]. CMML patients have monocytosis in the peripheral blood 
and morphologic dysplasia in the BM. The most commonly mutated genes are TET2, SRSF2 
and ASXL1 [19, 65]. CMML is a rare disease with an incidence of 1 in 100.000 per year, and 
the risk of progression to AML varies from 0% to 50% depending on risk group, and is 
associated with the presence of high-risk cytogenetics and high-risk mutations, e.g. ASXL1, 
RUNX1, SETBP1 and NRAS [65, 66]. 
1.6.2 Therapy-related AML 
The most common primary cancers prior to t-AML are lymphoma, breast cancer, multiple 
myeloma, ovarian cancer and testicular cancer [5, 7, 15]. It may also arise after autoimmune 
diseases, such as rheumatoid arthritis, treated with cytotoxic agents with or without 
immunosuppression [67]. Furthermore, there is an increased risk of AML in patients treated 
with azathioprine after solid organ transplantations, suggesting that apart from directly 
cytotoxic effects, immunomodulatory mechanisms might also contribute to t-AML [68, 69]. 
The risk of AML in patients treated with chemotherapy is 1.5 to more than 10 times higher 
compared to the population in general [70, 71], and varies according to type of primary 
cancer, chemotherapy regimens and accumulated doses of chemotherapy.  
1.6.2.1 t-AML following chemotherapy and radiation 
Traditionally, t-AML patients have been divided into two subgroups depending on the 
causative agent. The first well-characterized group of t-AML followed treatment with 
alkylating agents (e.g. cyclophosphamide, melphalan etc.) or radiation therapy. Alkylating 
agents cause cell death by crosslinking DNA, causing DNA double strand breaks followed by 
mutations and chromosomal rearrangements [72], which are thought to be leukemogenic, in 
particular when DNA repair systems are dysregulated [73]. Typically, deletions of the whole 
or parts of chromosomes 5 or 7, together with other MDS-like properties such as multilinear 
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dysplasia, can be seen after a latency period of 5-7 years [74, 75]. The other classic group of 
t-AML arises secondary to treatment with topoisomerase II inhibitors (e.g. doxorubicin, 
etoposide etc.). They block the DNA resealing step in the process of unwinding DNA during 
replication, causing double strand breaks [76]. Chromosomal aberrations typically associated 
with topoisomerase II inhibitors are balanced translocations, most commonly involving MLL 
(e.g. KMT2A) at 11q23 and RUNX1/AML1 at 21q22, but also to a lesser extent CBFB at 
16q22, as well as NUP98 at 11p15.5 [77, 78]. These patients have a shorter latency period of 
2-3 years and do in general not show a preceding myelodysplastic phase, but rather an abrupt 
onset of overt disease. The WHO previously subclassified t-AML based on the type of 
treatment mentioned above. However, since most cancer patients receive combination 
therapy this definition has been revised. Furthermore, although uncommon, t-AML may also 
occur after treatment with radioiodine for malignant and non-malignant thyroid diseases [79]. 
Apart from the aberrations described above, other well-known molecular features of t-AML 
that differs from de novo AML are the substantially higher frequencies of TP53 mutations 
[80, 81] and complex cytogenetics [6]. 
1.6.2.2 t-AML following autoimmune conditions 
Evidence from large epidemiological studies show a clear elevated risk of AML in patients 
with autoimmune conditions compared to the population in general, with odds ratios between 
1.3 - 1.7 [82-84]. Whether the reason is a shared genetic predisposition, 
immunological/inflammatory driven mechanisms or secondary to treatment is a complex 
issue. However, the over-risk has been shown to be confined to patients treated with 
cytotoxic therapy, indicating that immune mediated mechanisms have a minor role [84]. 
Treatment with azathioprine [85] and cyclophosphamide are associated with myeloid 
neoplasms while the role of methotrexate is uncertain [67]. On a related note, 
immunosuppression with azathioprine in the setting of organ transplantation shows a strong 
correlation with development of AML [69].  
1.7 GENETICS 
1.7.1 Chromosomal aberrations 
Chromosomal translocations that give rise to fusion genes have long been known to mediate 
acute myeloid leukemogenesis [86]. Typically, the resulting hybrid proteins dysregulate 
transcription factors involved in myeloid differentiation or involved in cell survival and 
apoptosis. In Swedish population-based data 43% of the patients had normal karyotype, 24% 
complex (at least 3 abnormalities) and (18%) monosomal karyotype [30]. The most common 
recurrent abnormalities were -5/del(5q) (13%), -7/del(7q) (13%), -17/del(17p) (8,8%), 
inv(16)(p13q22)/t(16;16)(p13;q22) (2,2%) and t(8;21)(q22;q22) (1,9%). These figures do not 
include APL, which constitute about 3,5% of all AML in Sweden. 
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1.7.2 Somatic mutations 
In 2008, AML was the first disease in which the whole cancer genome was sequenced [87]. 
The genetic diversity in AML is large, both regarding structural chromosomal variations and 
point mutations [2]; however, the median frequency of mutations is lower in AML than in 
most other cancers, but with large variations between individual patients [88]. AML is part of 
the Cancer Genome Atlas Program (TCGA), and in 2013 they published highly cited DNA 
and RNA sequencing data as well as DNA methylation results on 200 AML patients, 
although on de novo patients only [2]. Many comprehensive sequencing studies have been 
performed since then, including large numbers of patients with t-AML and AHD-AML, and 
it is reasonable to say that by now the mutational spectrum in the coding parts of the genome 
in AML is well characterized [89-91]. 
Since nearly half of the AML cases have normal cytogenetics, somatic point mutations and 
smaller copy number variations must play an important role in the disease pathogenesis. In de 
novo AML there is an average of 13 somatic mutations in the leukemic cells of each patient 
[2]. However, only 4-5 of these mutations are found in recurrently mutated genes [2, 89]. 
Virtually all cases have at least one driver mutation, and >85% at least two [2, 89]. However, 
the large published AML sequencing studies are not population-based, and age groups and 
subtypes are skewed. Furthermore, they use technologies with differences in gene coverage 
and sequencing depth. As a consequence, mutation patterns and frequencies are not always 
straightforward to compare between studies.  Nevertheless, the most commonly mutated 
genes in AML overall are FLT3 (30-35%), NPM1 (~30%), DNMT3A (20-30%), IDH1 or 
IDH2 (~20%), NRAS or KRAS (~15-25%) and TET2 (~10-15%), followed by a several genes 
with a frequency around 10% (RUNX1, CEBPA, TP53, WT1, ASXL1, PTPN11, SRSF2 etc.) 
[2, 89, 90]. 
The number of driver mutations per individual is highest in AHD-AML and lowest in t-AML, 
with de novo AML in-between [89].  A reason for the subtype differences could be that in t-
AML, structural chromosomal aberrations (rather than point mutations) are usually additional 
drivers, and in AHD-AML, with its older population, the higher frequency of mutations could 
be age acquired. 
Mutations in AML can be grouped according to functional categories (such as DNA-
methylation-related genes, tumor-suppressor genes and splice-factor genes) or grouped by 
patterns of cooperation and mutual exclusivity between genes. Either way, the groups 
correlate to clinical outcome and suggest specific patterns and underlying biology in disease 
development [2, 89, 90].  
There has been an increasing interest in the order of genetic events leading to AML and to 
disease relapse. Initiating genetic lesions, division of driver mutations versus passenger 
mutations and mechanisms of clonal evolution have been outlined [60, 92, 93]. For instance, 
mutations that have shown to be early and present in preleukemic cells have been found in 
DNMT3A, TET2 and ASXL1, genes that all are involved in epigenetic regulation [94-96]. 
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1.7.3 Genetic properties of secondary AML 
The division of AML into the three categories de novo, AHD- and t-AML is purely based on 
clinical information, that is, a history of either a antecedent hematological disorder or 
previous exposure to cytotoxic agents. While these subgroups have distinct differences in 
clinical characteristics and outcome at large, there is reason to believe that the underlying 
genetics explain the clinical phenotype even better than clinical history alone. By sequencing 
a large cohort of patients with de novo, AHD- and t-AML Lindsley and colleagues identified 
subtypes based on mutational signatures and clinical outcome: secondary-type (that is, 
secondary to MDS or CMML), TP53-mutated, de novo-type and PAN-AML-type [31]. 
The secondary-type mutations were in the genes SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, 
EZH2, BCOR and STAG2 (Figure 1), and they were highly specific to AHD-AML, but also 
found in the elderly de novo patients, while infrequently in younger patients. Cases with t-
AML were evenly distributed among the subtypes and were clinically more similar to non-t-
AML cases within the same mutational subtype than to t-AML at large (Figure 2). 
 
 
Figure 1. Specificity of myeloid driver mutations to secondary AML (AHD-AML). 
Reprinted with permission from American Society of Hematology (ASH): Blood, Acute 
myeloid leukemia ontogeny is defined by distinct somatic mutations, R. Lindsley et al, 
copyright 2015. 
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Figure 2. Mutations in therapy-related AML by mutational subtypes. Reprinted with 
permission from American Society of Hematology (ASH): Blood, Acute myeloid leukemia 
ontogeny is defined by distinct somatic mutations, R. Lindsley et al, copyright 2015.  
 
Furthermore, compared to de novo AML, t-AML has a markedly higher rate of high-risk 
aberrations, e.g. del(5q), -7/del(7q), del(17p)/t(17p)/-17 and TP53 mutations, while normal 
karyotype and favorable-risk abnormalities such as t(8;21) and mutations in NPM1 and 
DNMT3A are significantly underrepresented [2, 6, 21, 31, 89, 97]. Only few large sequencing 
studies have analyzed t-AML separately, nevertheless, in addition to TP53, the most 
commonly mutated genes are FLT3, the family of ABC transporter genes, PTPN11, IDH2 and 
NRAS [97, 98]. While there is a strong overrepresentation of high-risk cytogenetics in t-
AML, there is a large overlap between de novo and t-AML on a mutational level, and the 
study by Lindsley et al suggests that when adjusting for karyotype, de novo and t-AML have 
quite similar clinical and mutational profiles [31].  
1.7.4 Epigenetics 
Apart from mutations and chromosomal aberrations, epigenetic changes, i.e. DNA 
methylation by covalent modification of cytosine residues and various histone modifications, 
contribute to the disease development in AML [99]. In cancer in general, there is a global 
DNA hypomethylation and a hypermethylation of CpG islands of certain promoters. DNA 
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hypomethylation potentially causes chromosomal instability whereas promoter 
hypermethylation has been linked to silencing of tumor suppressor genes [100]. Genome 
wide DNA methylation profiling in AML has shown distinct patterns in different genetic 
subgroups and also that methylation pattern subtypes can classify AML into prognostic 
groups [41, 42, 101]. Epigenetics, chromosomal aberrations and somatic mutations are 
closely related. One example is recurrent chromosomal translocations leading to fusion 
proteins that alter the epigenome (e.g. MLL, a histone methyltranferase). Another example is 
that more than 70% of the AML cases have mutations in genes related to DNA methylation 
or histone modification [2]. 
1.7.4.1 Epigenetics in t-AML 
Only few studies have specifically described epigenetic changes in therapy-related AML. 
Radiation causing DNA strand breaks has been shown to induce DNA hypomethylation that 
is stable even after the DNA damage has been repaired [102]. Benzene, even though not used 
as a chemotherapeutic agent, is an alkylating agent, which causes both hypo- and 
hypermethylation [103]. Several studies have found aberrant methylation status in specific 
genes in t-AML. For example, the p15 promoter is commonly hypermethylated, both in 
diagnostic and preleukemic t-AML samples, which is also correlated to -7/del(7q) [104, 105]. 
Another example is DAPK1, a known cancer pathway gene, which is more commonly 
methylated in t-AML than de novo AML [106]. The methylation status of certain genes has 
also been correlated to the latency between the primary treatment and t-AML [107]. 
1.8 RECENT ADVANCES IN THE UNDERSTANDING OF THE BIOLOGY OF T-
AML 
Evidence are accumulating that the pathogenesis of t-AML is not fully explained by the direct 
mutagenic effects of cytotoxic therapy, but rather by several coexisting mechanisms such as 
the clonal selection of somatic driver mutations existing already before the treatment of the 
primary disease, abnormal microenvironment induced by chemo/radiotherapy, and in some 
cases inherited mutations associated with susceptibility for cancer [108]. 
By using whole-genome-sequencing, Wong and colleagues [97] found the mutational burden 
of TP53 to be similar in de novo and t-AML, and even though TP53 mutations were 
significantly overrepresented in t-AML compared to de novo AML, the number of somatic 
mutations within the TP53 gene was similar, implying that chemotherapy does not induce 
genome-wide DNA damage and does not cause the TP53 mutations. Instead the authors 
found TP53 mutations in preleukemic t-AML samples, even before start of treatment for the 
primary diagnosis, supporting the hypothesis that TP53 mutations confer a competitive 
advantage during the pressure of chemotherapy.  
Not only TP53, but several other genes usually associated with myeloid malignancies, most 
frequently DNMT3A, TET2 and ASXL1, are commonly mutated in the blood of healthy 
individuals, a phenomenon with a strong correlation to increased age and increased risk of 
hematologic cancer [94, 95]. This acquirement of somatic mutations in aged healthy 
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individuals is known as clonal hematopoiesis of indeterminate potential (CHIP) and is 
defined as the presence of mutated clones (>2% variant allele frequency) in the hematopoietic 
cells without cytopenias or dysplasias or other signs of hematological disease [109]. 
Already in the 1990s it was known that patients treated for cancers had a higher frequency of 
clonality in the blood of patients that had received chemotherapy, although that early only 
with evidence on chromosomal level [110]. We now know that preleukemic clonal 
hematopoiesis is found at a high frequency at the time of diagnosis of the primary cancer, 
even before start of therapy, in patients who later develop t-MN. We also know that patients 
with clonal hematopoiesis are at higher risk of developing t-MN than those without. In a 
case-control study, Takashi and colleagues detected clonal hematopoiesis in the peripheral 
blood in more than 70% of the patients who later developed t-MN but only in about ~30% of 
the controls that did not [111]. Healthy individuals with clonal hematopoiesis at risk of AML 
development can be identified and distinguished from other individuals with benign clonal 
hematopoiesis years prior to the onset of AML based on point mutations, where the 
preleukemic cases have more mutations, mutations enriched in specific genes (e.g. U2AF1, 
TP53 etc.) and higher allele frequencies than controls [112]. 
Thus, the pathogenesis of t-AML is most likely multifactorial. McNerney and colleagues 
propose an updated model of the development of t-AML (and t-MDS as well) that combines 
four different mechanisms (Figure 3) [108].  
1. The direct cytotoxic effects of chemotherapy and radiation on the DNA do induce 
genomic instability, chromosomal aberrations and likely mutations. 
 
2. As described above, pre-existing somatic mutations acquired before treatment, as part 
of clonal hematopoiesis, have a competitive advantage and are selected for by 
chemotherapy and/or radiation. 
 
3. In a subset of patients inheritance also matters. Germline mutations in pathways of the 
DNA repair systems are associated development of t-MN, and there may also be a 
genetic susceptibility for the independent development of a secondary cancer [113]. 
 
4. Furthermore, cytotoxic treatment likely damages the bone marrow niche causing 
abnormalities in the microenvironment, resulting in aberrant cytokine levels and 
altered cross talk between hematopoietic stem cells and other cells in the niche, 
providing an advantage for preleukemic clones [114]. 
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Figure 3. Contributions to the development of therapy-related myeloid neoplasms. 
Reprinted by permission from Springer Nature: Nature Reviews Cancer, Therapy-related 
myeloid neoplasms: when genetics and environment collide, M. McNerney et al, copyright 
2017. 
 
1.9 TREATMENT 
1.9.1 Classical induction treatment 
The principle of treatment of AML is to reduce the blast percentage below 5% through 
induction therapy and to reduce minimal residual disease by giving consolidation therapy. In 
the Swedish national guidelines the induction treatment consists of combination therapy with 
three days of daunorubicin and five days of cytarabine (DA3+5) [115]. This is comparable to 
the internationally more common 7+3 regimens, i.e. cytarabine continuously for 7 days with 
an anthracycline once a day for three days. Bone marrow is usually evaluated on day 25-28, 
and if complete remission is reached, 2-3 courses of consolidation therapy follow. If complete 
remission is not reached, reinduction with alternative drug combinations is given. In patients 
with intermediate and high risk cytogenetics, allogeneic hematopoietic stem cell 
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transplantation should be considered, but with careful consideration of other risk factors such 
as age, comorbidity and treatment response.  
In elderly patients or patients otherwise not fit for intensive treatment there are other 
treatment options, which although not aim for cure, can prolong survival and/or alleviate 
symptoms. These options are low-dose cytarabine, hypomethylating agents (HMAs), best 
supportive care with the option of cytoreductive drugs and transfusions, or merely palliative 
care. [116] 
1.9.2 Hypomethylating agents 
The HMAs azacitidine and decitabine are widely used for the treatment of MDS. In AML, 
they are primarily a treatment option for patients not eligible for intensive induction. They 
can also be used as bridging to HCT in selected subgroups of patients [117, 118], and can 
potentially have a place as maintenance treatment after remission in elderly patients ineligible 
for HCT [119]. Treatment with HMAs in patients with s-AML is an appealing option due of 
the overrepresentation of typical adverse risk aberrations such as complex or monosomal 
karyotypes, abnormalities in chromosome 5, 7 and 17, and TP53 mutations that might predict 
response to HMAs [6, 120, 121]. 
1.9.3 Treatment aspects of s-AML 
Boddu and colleagues compared treatment results of patients with s-AML treated with either 
cytarabine based intensive treatment, HMAs, low-dose cytarabine, CPX-351 (se below) and 
investigational agents [122]. The survival was overall poor, but the authors conclude that 
lower intensity approaches have lower rates of early death rates and improved OS compared 
to intensive treatment. Older data also supports the rationale to spare intensive treatment in 
high-risk disease even in fit patients, and only treat low-risk s-AML patients intensively 
[123].  
Conversely, in Swedish population-based data intensive treatment is tolerable in the elderly, 
and improves early death rates and prolongs survival compared to palliative treatment [1, 
124]. In view of the understanding that s-AML patients share genetic properties with elderly 
[31], they also ought to benefit from intensive treatment. 
The challenges of treating s-AML and other AML high-risk groups, especially in the elderly, 
are not only to choose the treatment option that has the highest probability of prolonged 
survival, but also to decide when not to treat intensively or when not to proceed to HCT when 
chances of long-term survival are futile, and there is a high risk of treatment morbidity or 
reduced quality of life. 
1.9.4 New treatment options 
The classical induction treatment described above has been virtually unchanged for 40 years 
[4]. However, during the last few years several new drugs have shown efficacy in 
subpopulations of AML. Since 2017, midostaurin, gemtuzomab ozogamicin and CPX-351 
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have been approved in Europe, and in the U.S. also venetoclax, ivosidenib, and glasdegib 
(Figure 4). New therapy options are of course welcome, in particular for s-AML and the 
elderly, where current regimens are insufficient. However, criticism has been raised over 
issues in the approvals: lack of randomized studies, problematic endpoints, ill-defined 
inclusion criteria (e.g. "unfit"), and approvals for patients not included in the studies [125]. 
Hopefully, large randomized studies together with real-world data will eventually answer 
these questions. 
 
Figure 4. Developments in the treatment of AML. Reprinted by permission from Springer 
Nature: Nature Reviews Clinical Oncology, Advances in patient care through increasingly 
individualized therapy, CD. DiNardo et al, copyright 2018. 
  
Liposomal cytarabine and daunorubicin for induction treatment 
Aimed specifically at older patients with s-AML is CPX-351. This is a combination of 
cytarabine and daunorubicin in a liposomal encapsulations which has shown improved OS 
compared to conventional 7+3 induction and consolidation in a large phase III study 
including t-AML, AHD-AML and AML with dysplasia-related cytogenetic abnormalities 
[126].  
Gemtuzomab ozogamicin in addition to standard induction 
Gemtuzomab ozogamicin (GO), which is a conjugate between a CD33 antibody and 
cytotoxic drug, was in use already in the early 2000, but was withdrawn due to toxicity and 
no survival advantage. However, newer data has shown efficacy in favorable and 
intermediate risk groups [127]. As of 2019, GO is recommended as an addition to standard 
induction only in patients with CBF de novo AML. Thus, this is not an option for patients 
with s-AML. 
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Venetoclax for patients ineligible for intensive treatment 
Venetoclax, an oral BCL-2 inhibitor, is approved in the US in combination with HMAs or 
low-dose cytarabine for first-line treatment of older patients or those unfit for intensive 
induction. Response rates and median survival (over 16 months) in this elderly group 
(including a large proportion of patients with s-AML and adverse risk cytogenetics) was 
impressive in the phase I study that lead to the US regulatory approval [128]. 
FLT3 inhibitors as addition to induction, maintenance or salvage therapy 
The most commonly mutated gene in AML is FLT3, while highly enriched in de novo AML 
(24-28% of cases), it is less frequently mutated in t-AML (8-16%) and AHD-AML (19%) [2, 
31, 97]. Multiple kinase inhibitors that target FLT3, along with other kinases with varying 
specificity, are available or being studied both in AML and other malignancies [129]. In the 
current Swedish guidelines (2019)[115], midostaurin is recommended as addition to standard 
induction therapy in FLT3 mutated patients <70 years, based on the phase III study that 
showed a significant lower hazard ratio for death compared to placebo [130]. Several other 
FLT3 inhibitors have been developed and are investigated for use during induction, as 
maintenance therapy or for relapsed or refractory AML [131, 132]. 
IDH inhibitors  
IDH1/2 mutations occur in 20% of AML, however the frequency in t- AML and s-AML is 
estimated to only 5-10%. Enasidenib targeting IDH2 and ivosidenib targeting IDH1 have 
shown promising results in Phase I and II studies, and both drugs are approved by the FDA 
for use in relapsed/refractory AML [133, 134]. It has also shown efficacy in older newly 
diagnosed patients, including patients with AHD-AML [135]. Ongoing studies are 
investigating IDH inhibitors in combination with azacitidine [136] and as addition to 
induction/maintenance treatment [137].  
Glasdegib for elderly patients not fit for intensive treatment 
The Hedgehog signaling pathway is important for leukemic stem cell maintenance and 
inhibition of this pathway increases sensitivity to chemotherapy [138]. Glasdegib is an oral 
Hedgehog pathway inhibitor and is approved in the U.S for use with low-dose cytarabine in 
older patients or in patients with comorbidities that prevent them from receiving intensive 
treatment. The approval study included patients with secondary AML and showed a median 
OS of 8.3 months compared to 4.3 months with low-dose cytarabine alone [139]. 
Oral azacitidine as maintenance therapy 
Oral azacitidine as maintenance therapy has been presented as an effective maintenance 
therapy after complete remission in patients (both de novo and s-AML) ineligible for HCT 
with 24.7 months OS compared to 14.8 months in the placebo group [140]. 
To summarize, the current treatment approaches in s-AML patients are inefficient, and there 
is evidently a hitherto unmet need for improvement. However, even though the novel 
treatment options are interesting, they do not prolong survival more than a few months 
compared to control arms, and real-world data will eventually test their efficacy.   
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1.10 FOLLOW-UP / MEASURABLE RESIDUAL DISEASE 
Morphological evaluation is a too imprecise method to detect imminent relapse or residual 
leukemia cells after treatment. Instead, measurable residual disease (MRD) by using either 
flow cytometry or molecular methods can identify patients at high risk of relapse and to guide 
treatment [17]. The flow cytometry approach is based on finding either a leukemia-associated 
immunophenotypes (LAIP) or a phenotype that is aberrantly differentiated compared to 
normal (DfN, different from normal), or a combination of both. Molecular methods using 
real-time quantitative PCR (RT-qPCR) to detect MRD can be even more sensitive than flow-
based approaches and are currently used to analyze NPM1 mutations, t(15;17), t(8;21) and 
inv(16) [141]. Additional methods with even higher sensitivity, e.g. digital droplet PCR and 
NGS, are likely to be used in the future [142]. MRD usage depends on the clinical situation, 
but is especially useful to guide HCT in low-risk patients with detectable MRD in CR1, to 
refrain HCT in intermediate-risk patients with low risk of relapse, to identify patients with 
elevated relapse risk post-HCT and to monitor patients after treatment [17].  
1.11 ALLOGENEIC STEM CELL TRANSPLANTATION 
HCT is a potentially curable treatment primarily used as post-remission therapy in younger 
patients in the intermediate or adverse risk groups [23, 143, 144], but is also an option in 
relapsed or refractory AML [145, 146]. Genetic risk, age, comorbidities, treatment response 
and availability of a donor form the basis of transplant decisions [3, 22]. The transplantation 
is preceded by a combination of chemotherapy and immunosuppression, and the conditioning 
can either me myeloablative (MAC) or reduced (RIC). HCT is a complex procedure with a 
significant risk of complications, including transplant related mortality (TRM) and graft-
versus-host disease (GvHD), both acute and chronic [147, 148].  
The role of HCT in s-AML is less studied than in de novo AML, however in the majority of 
patients with s-AML HCT should be considered, since these patients are characterized by 
non-favorable genetics. Data on transplant related factors of importance and outcome specific 
for s-AML has historically been scarce. However, during 2018-2019 the European Society 
for Blood and Marrow Transplantation (EBMT), mostly through the work of the Acute 
Leukemia Working Party, published a series of reports on various aspects of allogeneic 
transplantation based on large numbers of s-AML patients [149-156]. They show that s-
AML, compared to de novo AML, is a risk factor for relapse and survival after HCT [150, 
154]. Within AHD-AML, prior diagnosis of MPN rather than MDS is associated with worse 
OS, along with age, unrelated donor, CMV mismatch, Karnofsky index <= 80, remission 
status and peripheral blood as stem cell source [152]. Moreover, in patients with s-AML and 
similar to AML in total, limited chronic GvHD is associated with longer survival, while 
worse OS is seen in patients with grade II-IV acute and extensive chronic GvHD [149]. 
Regarding conditioning regimen, MAC is preferable to RIC in prolonging OS in patients with 
s-AML [155, 156]. In the subgroup of t-AML with a prior lymphoma, MAC was also 
preferable to RIC, and patients previously treated with autologous HCT had inferior 
leukemia-free survival [151]. Haploidentical transplantation seems feasible in s-AML with 
 20 
similar impact of anti‐thymoglobulin vs. post‐transplant cyclophosphamide and choice of 
conditioning intensity as in de novo AML [153]. While the large EBMT studies are valuable 
sources of information, prospective trials about s-AML and HCT are still lacking. 
1.12 HEALTH CARE AND QUALITY REGISTRIES 
There is a long history of centrally administered health registries and disease specific 
healthcare quality registries in Sweden. The clinical data available therein and the possibility 
to cross-link them, are useful resources both for research and for improvement of quality of 
care [157].  In addition to the Swedish Acute Leukemia Registry (SAMLR), two other 
registries are of importance in the context of s-AML. The Swedish Cancer Register (SCR) 
and the Swedish Rheumatology Quality Register (SRQ). They can be used for data 
validation, give detailed information about prior diagnoses, including international 
classification of diseases (ICD) codes and dates of diagnoses and, in particular, aid the 
classification of s-AML. 
All adult patients diagnosed with AML in Sweden are reported to SAMLR. The treating 
physician is responsible to report to the registry at several time-points during the time from 
diagnosis to a possible transplantation or relapse. The reporting system is web-based, and late 
or missing reports are actively requested. Since the start in 1997 the registry has grown to 
include over 250 variables. It has been validated against the SCR and found to have a 
coverage of 98% of all patients with a diagnosis of AML [1].  
Both clinicians and pathologists are obliged to report all new cancer diagnoses to SCR. The 
diagnoses can be based on clinical, morphological and other laboratory exams. Data 
contained in SCR include basic patient data, diagnostic dates and ICD codes for tumor site 
and histological type. Since it was founded in 1958 it enables long follow-up of outcomes, 
including secondary malignancies [158]. 
SRQ was initiated in 1996 and encompasses 89,000 patients and more than 100 rheumatic 
diseases. Data include patient information, ICD codes, treatment and follow-up [159] 
Studies using population-based registry data complement basic research and clinical trials. 
Although a clinical trial is the gold standard for evaluating an intervention, many trials have 
narrow inclusion criteria and are not generalizable to a broader population, and for some 
clinical questions randomized controlled trials will have issues with patient numbers, logistics 
or other resources [160].  
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2 AIMS 
2.1 OVERALL AIM 
The overall aim of this thesis was to define clinical, molecular and epidemiological 
characteristics of secondary AML. 
2.2 SPECIFIC AIMS OF THE STUDIES 
 
Study I 
1. Test the feasibility of high-throughput mutation screening in MDS and AML 
2. Identify mutational patterns with relevance for prognosis and progression from MDS 
to AML 
 
Study II 
1. Compare characteristics and outcome between s-AML and de novo AML 
2. Validate, in a population-based setting, if s-AML in itself is a useful prognostic 
marker independent of established risk factors 
 
Study III 
1. Compare HCT with conventional post remission therapy (CPRT) in s-AML 
2. Compare s-AML with de novo AML in patients undergoing HCT 
 
Study IV 
1. Investigate the incidence of t-AML over time 
2. Identify prognostic factors in t-AML 
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3 METHODOLOGICAL APPROACHES 
3.1 STUDY I 
3.1.1 Patients and samples 
Consecutive diagnostic bone marrow samples stored in the Karolinska Institutet MDS and 
AML research biobanks fulfilling the predetermined classification requirements were 
selected. Among the cases with MDS, the WHO 2008 [161] subtypes considered were 
RCMD-RS, RARS, RARS-T (grouped together as "RS"), 5q-, RCMD, RAEB-I, RAEB-II 
and CMML. In AML, only non-de novo cases were included, that is, AHD-AML, t-AML and 
AML with specific MDS associated cytogenetic aberrations (according to the definition of 
AML with myelodysplasia-related changes, WHO 2008 [161]). The patients were treated 
following national guidelines. Clinical data were collected from local registries, electronic 
patient records and the Swedish AML registry. Samples from 20 healthy donors were used as 
controls.  
3.1.2 Mutational analyses 
To screen for mutations, a three-step pipeline was followed. First the exons of the 22 selected 
genes were amplified using Halogenomics target amplification technology (Halogenomics 
AB, Uppsala, Sweden). To make this cost-effective, the samples were pooled in groups of 10. 
Each pool was marked and identified by a introducing a 6 base-pair barcode. Secondly, the 
pools were sequenced in two runs using Illumina Hiseq 2000 sequencing system. Next, 
sequencing data were filtered based on the barcodes and mapped onto a reference genome 
(The 1000 Genomes Project) and all the single nucleotide polymorphisms (SNPs) were 
filtered out based on SNP databases (SNP-DB). Third and last, the mutations in the individual 
patients were verified using the Sequenom system, which is a high-throughput system to 
analyze point mutations and SNPs. Additionally, hotspot mutations in the three splicing genes 
SRSF2, SF3B1 and U2AF1, not included in the original gene list, where analyzed. 
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3.2 STUDY II - IV 
3.2.1 Patients 
These observational registry studies were based on adult (18 years or older) patients in the 
Swedish AML registry. Table III summarizes the numbers and subtypes of the included 
patients for each study.  
 
Table III. Number and subtypes of patients included in studies II - IV.   
 Study II Study III Study IV 
Study description Characterization and 
outcome in patients 
with s-AML 
The impact of HCT in 
patients with s-AML 
Characterization and 
outcome of patients with 
t-AML 
Study period 1997-2007 1997-2013 1997-2015 
Number of patients 
diagnosed with AML 
3363 5873 6779 
Included for analyses All 3363 AML patients All 3337 intensively 
treated non-APL AML 
patients 
All 5492 patients with 
either de novo or t-AML 
         de novo AML 2474 2613 4806 
         AHD-AML 630 442 - 
         t-AML 259 282 686 
Additional data 
sources 
- Swedish cancer 
registry 
The 6 transplantation 
centers in Sweden 
Swedish cancer registry 
Swedish Rheumatology 
Quality registry 
 
3.2.2 Data collection and definitions 
Apart from the Swedish AML Registry, data were collected from the Swedish cancer 
registry, the Swedish Rheumatology Quality registry and local registries at all 6 
transplantation centers in Sweden. Patients were classified into the three subgroups, de novo 
AML, AHD-AML and t-AML. AHD-AML was defined as cases diagnosed with a prior 
hematologic disorder, essentially the myeloid neoplasms MDS, CMML and MPN. T-AML 
was defined as AML with a prior diagnosis of a malignancy or a non-neoplastic disease 
treated with chemotherapy and/or radiation therapy, but not immunosuppressive treatment 
alone. Patients treated with chemotherapy for a myeloid antecedent hematologic disorder 
were classified as AHD-AML and patients treated with chemotherapy or radiation for a non-
myeloid disease (e.g. lymphoma or multiple myeloma) were classified as t-AML. Patients 
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treated with chemotherapy/radiation for a primary disease who developed MDS or MPN in-
between the therapy and the diagnosis of AML were classified as t-AML.  
3.3 STATISTICAL CONSIDERATIONS 
Throughout the studies, all tests were two-sided with a significance threshold of 0.05. 
Categorical data were compared using either Pearson's chi-squared test or Fisher’s exact test 
(depending on sample size). Survival analyses were central in all four studies and estimation 
and visualization of survival was performed using the Kaplan-Meier method and comparisons 
between groups using the log-rank test. Although this method is adequate for crude 
comparisons, it does not accommodate analyses of multiple covariates. Instead, for 
multivariable analysis of survival, Cox proportional hazards regression was used. This 
method assumes that the rate of events is proportional between the groups compared, which 
was tested using inspection of the scaled Schoenfeld residuals. To limit immortal time bias in 
comparisons between HCT vs. CPRT in study III landmark techniques and Cox regression 
including HCT as a time-varying covariate was used. In addition, propensity score matching 
was used to balance groups when comparing HCT with CPRT. Multiple imputation was used 
in study II to test the impact of missing data. 
3.4 ETHICAL CONSIDERATIONS 
The benefits of increasing the knowledge about AML, with the goal of optimizing treatment 
methods of individuals, must be weighed against the cost and resources used for both the 
research in itself, but also for the clinical implications the results might have. Regarding 
personal integrity, all patient data used in this thesis were anonymized, without the possibility 
to identify specific individuals, and should not pose any risk of personal harm. The vast 
majority of patients included were deceased already at initiation of the studies, simply 
because of the short survival of AML. The possibility of renewed consent or possibility of 
changing their treatment was therefore impossible. Consequently, the patients included will 
not themselves benefit from any results. In study I, informed consent was obtained from all 
patients and healthy controls. There was a risk that the molecular analyzes could have 
detected hereditary genetic defects of importance to relatives to patients. However, although 
samples were unidentified they were traceable to the each individual.  Regional ethical 
review boards approved all studies. In summary, the assumed benefits of the studies are 
judged to outweigh any risks.  
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4 RESULTS 
4.1 STUDY I 
We performed targeted exon sequencing of 22 genes in 100 patients with MDS and 92 with 
AML. The AML cases were either therapy-related, progressed from MDS or MPN, or had 
MDS-like-cytogenetics. MDS included both low hand high-risk patients with the subtypes 
MDS-RS, del(5q) syndrome, RCMD (MDS-MLD, WHO 2016), RAEB I and II (MDS EB-1 
and EB-2, WHO 2016)  and CMML. 
Mutations were found in 61% of the MDS and 50% of the AML patients. Overall, the most 
frequently mutated genes in MDS were SF3B1, TET2, SRSF2 and IDH2 and in AML TET2, 
SRSF2, U2AF1 and IDH2.  Mutational patterns differed between subtypes in both MDS and 
AML. As expected, in MDS, del(5q) syndrome had the lowest frequency of mutations, and 
splice factor SF3B1 mutations were dominant in RARS and RCMD-RS. The MDS-AML 
subgroup shared mutations with high risk MDS with frequent mutations in splicing and 
epigenetic genes. MPN-AML was different from the other AML subtypes with a higher 
incidence of mutations in signaling and oncogenes (Figure 5). T-AML had a relatively low 
mutational burden at 33%, but a high rate of cytogenetic aberrations (87%). 
 
 
Figure 5. Proportion of patients with mutations in defined functional gene categories. 
(A) MDS subgroups (n=100) (B) AML subgroups (n=92). 
 
To investigate mutations associated with progression from MDS to AML, we compared the 
39 cases with either MDS with a subsequent AML progression or AML with an antecedent 
diagnosis of MDS with all the 89 MDS cases without AML progression. U2AF1 was the only 
gene significantly associated with progression (21% of transformed vs. 4% non-transformed, 
p=0.008). In contrast, and as expected, there was a negative correlation between mutated 
SF3B1 and leukemic progression (22% of non-transforming vs. 3% transformed, p = 0.004). 
 28 
We then assessed if the presence of mutations added prognostic information. The MDS 
patients were divided into two groups, IPSS-R very low, low and intermediate risk versus 
high and very high risk. Overall and progression-free survival was compared between 
patients without any mutation and patients with one or more mutations (SF3B1 excluded). 
Patients with mutations had worse OS and progression free survival in both risk groups (p < 
0.001), log-rank. In the same manner we divided AML into favorable and intermediate risk 
versus adverse risk and compared outcome in patients with or without presence of mutations. 
No difference could be seen in the adverse risk group in contrast to favorable/intermediate 
risk, where mutational status separated the group (p < 0001, log-rank). 
The influence of specific mutations on MDS to AML progression was explored using Cox 
regression analysis. In univariable models, SF3B1 had a strong positive impact whereas 
SRSF2, IDH2, U2AF1 and RUNX1 were negative prognostic markers. However, when 
adjusting for age, sex and IPSS-R, only SF3B1 and U2AF1 remained statistically significant. 
Corresponding analysis in AML yielded TP53 and NRAS as significant negative markers, 
also after adjusting for age, sex and cytogenetic risk. 
4.2 STUDY II 
Of the 3363 patients included in the study, 2474 (74%) were de novo AML, 630 (19%) were 
AHD-AML, and 259 (8%) were therapy-related. Median age was 70 in both t-AML and de 
novo AML, but slightly higher in AHD-AML at 71 years (p <0.001).  The gender balance 
was equal in de novo AML, predominantly female in t-AML (165 female, 64%, p <0.001) 
and predominantly male in AHD-AML (363 male, 58%, p <0.001). Adverse cytogenetic risk 
was most common in t-AML (46%) but also more common in AHD-AML (40%) than in de 
novo AML (20%). Favorable cytogenetic risk was rare in AHD-AML but similar in t-AML 
and de novo AML (8-9%). 
The prior diseases in AHD-AML were MDS in 404 (64%) patients and MPN in 187 (30%). 
The median latency period between the diagnosis of MDS and AML was 1.1 year and 
between MPN and AML over 7 years. The most common primary diseases in t-AML were 
breast cancer (n=55, 21%), non-Hodgkin lymphoma including CLL (n=50, 19%), 
uterine/cervical cancer (n=18, 7%), rheumatoid arthritis (n=18, 7%) and multiple myeloma 
(n=17, 7%). The median latency period between prior diseases and t-AML was 5.8 years for 
malignancies and 14.3 years for non-neoplastic diseases. 
Intensive treatment was more common in de novo AML. Among patients younger than 65 
years, 94% received intensive treatment compared to 69% in AHD-AML and 82% in t-AML. 
In addition, CR rates were lower in both AHD-AML and t-AML compared to de novo AML 
(39%, 54% and, 72% respectively, p < 0.001). Early death rates (death within 30 days of 
diagnosis) were similar between groups. 
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Table IV. Multivariable analysis for OS in intensively treated AML patients. 
 Overall  After CR 
 HR (95% CI) P  HR (95% CI) P 
Age—each 10 year increase 1.40 (1.33–1.47) <0.001  1.46 (1.37–1.55) <0.001 
Male vs. female 1.31 (1.16–1.48) <0.001  1.29 (1.11–1.50) <0.01 
AHD-AML vs. de novo AML 1.51 (1.26–1.79) <0.001  1.59 (1.23–2.05) <0.001 
t-AML vs. de novo AML 1.72 (1.38–2.15) <0.001  1.63 (1.20–2.23) <0.01 
Favorable vs. intermediate cytogenetic 
risk 
0.51 (0.38–0.68) <0.001  0.40 (0.28–0.56) <0.001 
Adverse vs. intermediate cytogenetic 
risk 
1.66 (1.46–1.89) <0.001  1.51 (1.26–1.80) <0.001 
 
In crude analyses, AHD-AML and t-AML had inferior OS compared to de novo AML. This 
was consistently seen in both intensively treated patients and overall, in both younger and 
older patients and across all cytogenetic risk groups. In the same manner, both types of 
secondary AML were inferior to de novo AML when comparing survival after the date of 
CR. In multivariable analysis (adjusting for age, sex, type of AML and cytogenetic risk 
group) both AHD-AML and t-AML had a significant negative impact on survival (t-AML vs. 
de novo HR 1.72; CI 1.38-2.15 and AHD-AML vs. de novo HR 1.51; CI 1.26-1.79) (Table 
IV). Subgroup analysis revealed that the prognostic effect of s-AML varied among age 
groups. In patients younger than 55, secondary AML had a markedly stronger negative 
impact on survival than in patients aged 55 or older. This age-dependent effect of s-AML on 
survival was apparent when comparing median OS between age groups: 158, 16 and 7 
months in patients with de novo AML aged <55, 55-74 and >= 75 years respectively, 
compared to 14, 9 and 8 months in t-AML, and 7, 7 and 6 months in AHD-AML. 
4.3 STUDY III 
There were 3337 intensively treated AML patients (APL excluded) during 1997-2013. Of 
these, 282 (8%) had t-AML, 442 (13%) AHD-AML and 2613 (78%) de novo AML. The 
antecedent disorders in AHD-AML were MDS in 311 (9% of total) and MPN in 130 (4% of 
total) patients. Gender distribution and rates of CR were similar to study II. HCT, regardless 
of disease state, was performed in 22% (n=576) of patients with de novo AML, 20% (n=57) 
of t-AML and 17% (n=74) of AHD-AML. The proportion of patients in CR1 who underwent 
HCT was 23% in de novo, 28% in AHD-AML and 27% in t-AML. 
Of patients transplanted in CR1, the median age was higher in AHD-AML than in de novo 
and t-AML (58 years vs. 48 and 51 years, respectively, p < 0.001). Moreover, in patients 
transplanted in CR1, adverse cytogenetic risk was more common in the two groups of s-AML 
compared to de novo AML. Myeloablative conditioning was given in 63% of s-AML patients 
who underwent HCT in CR1, 61% received a graft from an unrelated donor and 39% from a 
related donor, and in 89% of cases the stem cell source was peripheral blood. Transplanted 
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patients with AHD-AML and t-AML were similar regarding conditioning intensity, donor 
type, stem cell source, sex incompatibility, EBMT score and time from CR1 to HCT. 
 
 
Figure 6. Subgroup analysis showing the impact of allogeneic HCT versus CPRT on 
survival. 
 
In crude comparisons, s-AML had inferior OS compared to de novo AML, both overall and 
after the date of HCT in patients transplanted in CR1 (p < 0.001 and p = 0.005 respectively, 
log-rank). We compared HCT with chemotherapy only as postremission therapy in s-AML 
using three different statistical approaches. First, in a day 200 landmark analysis of non-
favorable risk patients younger than 65 years who reached CR1, HCT was advantageous to 
CPRT (p = 0.04, log-rank). Similar results were found when choosing 300 days as the 
landmark cutoff. Secondly, in the same group of patients, we performed a multivariable Cox 
regression with HCT as a time-varying covariate, adjusting for subtype of AML, cytogenetic 
risk and stratifying by age. The hazard ratio for HCT vs. CPRT overall was 0.73 (CI 0.64-
0.83), and in subgroup analysis both AHD-AML and t-AML had a significant negative 
impact on survival (Figure 6). Third, we performed a propensity score matching analysis 
comparing HCT and CRPT. Patients were matched on type of s-AML, cytogenetic risk, age 
and year of diagnosis and patients with CR1 < 90 days were excluded. 45 patients who 
underwent HCT were matched with 66 patients treated with CPRT. OS in the HCT group 
was longer than in the CPRT group (p = 0.021, log-rank). Altogether, the three methods all 
found HCT to outperform CPRT in patients with AHD- and t-AML. 
Furthermore, in multivariable analyses, the only transplant-related factors associated with 
prognosis after HCT was mild chronic GvHD vs. no chronic GvHD and absence of acute 
GvHD grade < I. 
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4.4 STUDY IV 
During the period 1997-2015 a total of 6779 individuals were diagnosed with AML of which 
686 (10%) were t-AML, 4806 (71%) de novo AML and 1287 (19%) AHD-AML. 
Comparisons of patient characteristics between t-AML and de novo AML were consistent 
with study II, showing similar median age (71 vs. 70), similar performance status, female 
predominance in t-AML (57% vs. 49%), and a higher frequency of adverse but lower 
frequency of favorable risk in t-AML (46% vs. 28% and 12% vs. 16% in adverse and 
favorable risk respectively). The proportion of APL was similar in t-AML and de novo AML 
(4% vs. 5%). Both the rate of receiving intensive induction and the rate of CR were lower in 
t-AML than in de novo AML (60% vs. 70%, p < 0.001 and 58% vs. 75%, p < 0.001, 
respectively). Patients with t-AML were less likely to undergo HCT (9% vs. 16%, p < 0.001) 
than patients with de novo AML. 
There was a steady rise in incidence of t-AML over study period. The mean age-standardized 
incidence rate increased from 0.39 cases per 100,000 during 1997-2006 to 0.63 during 2007-
2015 (p = 0.004). Similarly, the estimated annual percentage change in incidence rate of t-
AML was 4.5% (CI 2.8% - 6.2%). This was higher than the estimated annual percentage 
change in de novo AML (0.7%, CI 0.2% - 1.2%) and in AML in total (1.2%, CI 0.7% - 
1.7%). Consequently, the proportion t-AML of AML in total increased from 8.3% 1997-
2006 to 11.8% 2007-2015 (p = 0.004).  
The most common primary diagnoses prior to t-AML were lymphoma (n=139), breast 
cancer (n=124), gynecological malignancies (n=60), prostate cancer (n=47), rheumatic and 
inflammatory disease (n=47), gastrointestinal cancer (n=36), and multiple myeloma (n=33). 
In total, 55% of the primary diseases were solid cancers, 25% hematological cancers and 
18% non-malignant diseases. Multiple prior diseases were common; 19% of the patients 
had more than one malignancy reported and 17% had a diagnosis of MDS between the 
primary diagnosis and the onset of AML. There were large variations in the latency periods 
between the primary disease and AML. The median latency period after hematological 
malignancies was 57 months, after solid cancers 61 months and after non-malignant disease 
173 months (p < 0.001). 
 
Table V. Crude 5-year survival rates and median survival in patients with t-AML and de novo AML. 
 t-AML  de novo AML 
 5-year OS Median OS 
(months) 
 5-year OS Median OS 
(months) 
Overall 10% 5.0  23% 9.7 
Intensively treated 17% 9.5  34% 20.7 
Patients subjected to HCT 48% 48  57% 113 
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Crude (unadjusted) survival data are shown in Table V. The median OS in t-AML in total 
was 5.0 months, in intensively treated patients 9.5 months and in patients who underwent 
HCT 48 months (corresponding OS in de novo AML was 9.7, 20.7 and 113 months 
respectively). The difference in outcome between t-AML patients with or without an 
intermediate diagnosis of MDS that was found in univariable analyses (HR 1.52, CI 1.09 - 
2.12, p = 0.013) was non-significant after adjustment for age and cytogenetic risk (HR 1.28, 
CI 0.89 - 1.87, p = 0.185).  There were no significant survival differences between treatment 
modalities of the primary disease (radiation vs. chemo, HR 1.01, CI 0.72-1.41 and 
radiation/chemo vs. chemo alone, HR 1.36, CI 0.96-1.41, adjusted for age, risk and 
performance status). 
There was no significant survival difference between t-AML and de novo AML among 
favorable risk patients (t-AML vs. de novo AML, HR 1.11 CI 0.62 - 1.97, p = 0.73) when 
adjusting for age and performance status. In contrast, with the same adjustments, t-AML had 
a strong negative impact in the intermediate and adverse risk groups (t-AML vs. de novo 
AML, HR 1.53, CI 1.25 - 1.87, p < 0.001 and HR 1.59, CI 1.31 - 1.93, p < 0.001, 
respectively). Additionally, t-AML patients with the combination of mutated NPM1 and 
absence of FLT3-ITD had longer OS than patients with other combinations of NPM1 and 
FLT3-ITD (p = 0.019, log-rank). In the subset of patients with the favorable combination 
NPM1+/FLT3-ITD-, OS was similar in t-AML and de novo AML, both in crude comparison 
(p = 0.58, log-rank) and after adjusting for age, performance status and risk (t-AML vs. de 
novo AML, HR 0.75, CI 0.36 - 1.58, p = 0.454). 
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5 DISCUSSION 
5.1 NGS MUTATIONAL SCREENING 
The question posed in study I, whether high-throughput mutational screening is feasible, is 
no longer debatable. NGS, usually implemented as gene panel assays, are already part of 
clinical routine for diagnostic profiling, prognostication and identification of possible drug 
targets in MDS and AML [162-164]. On the other hand, the other main finding, that mutated 
U2AF1 is an adverse prognostic marker for OS and AML progression in MDS, is in hindsight 
not as certain. Other small series have found similar results, either for transformation only 
[165] or both transformation and OS [166], while others conclude that U2AF1 has no 
prognostic value [167, 168]. Studies in lower-risk MDS have found U2AF1 not to be of 
significance after adjusting for risk adapted prognostic scores [169], while more recent data 
suggests U2AF1 (as well as several other genes) only to have independent prognostic value in 
patients with <5% blasts [170]. Finally, in a large meta-analysis of 3322 de novo MDS 
patients of which 390 patients had mutated U2AF1, the mutation did indeed have a 
prognostic impact on both OS and AML transformation [171].  
This highlights the fact that in many cases different studies reach conflicting conclusion when 
it comes to the impact of specific mutations, not only U2AF1. The reason is probably a 
combination of sample size, varying inclusion criteria, ages and different subgroups of 
patients. Usually, most commonly mutated genes have a significant negative impact in 
univariable analyses, however when adjusting for other genes and known clinical risk factors 
the number of significant gene mutations are considerable fewer. Thus, the issue of 
prognostic impact of specific genes is highly complex, and it is important that the impact of 
specific gene mutations are thoroughly validated, preferable in large collaborative groups, 
before implementation in clinical guidelines that influence patient management. 
5.2 AGE AND S-AML AS AN ADVERSE RISK FACTOR 
It is well known that age, along with cytogenetic risk, is the most important prognostic factor 
in AML. Study II found both t-AML and AHD-AML to be additional negative prognostic 
factors for OS, also when adjusting for age, sex, and most important, cytogenetic risk. 
However, two age-related findings were notable. First, while CR rates were substantially 
higher in younger than older patients with de novo AML, they were similar between age 
groups in s-AML. Secondly, the adverse prognostic impact of s-AML, in particular of AHD-
AML, was age-dependent. Having s-AML in older age did not add any prognostic 
information, while it was a strong negative marker in the younger, who had almost as poor 
outcome as the elderly. These results are in line with Danish population-based data have also 
shown that intensively treated patients >60 years old with t-AML and MDS-AML have 
similar outcomes as de novo AML when adjusting for performance status, comorbidities and 
cytogenetics [5]. And as mentioned in the introduction, others have also noted this lack of 
prognostic impact of s-AML in the elderly [5, 6, 27]. The obvious explanation is the high 
prevalence of both adverse-risk cytogenetic aberrations and high-risk mutations across ages 
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in s-AML, in contrast to AML in total, where high-risk genetics are much more common in 
the elderly [30, 172]. Moreover, on the mutational level, one third of elderly de novo patients 
share genetic features with AHD-AML, suggesting an undiagnosed MDS-phase before 
presenting as de novo AML [31].  
5.3 SUPPORT FOR HCT IN S-AML 
With such dismal survival rates without HCT as presented in study III, it is hard to convince 
physicians and patients to take part in a randomized trial comparing HCT with CPRT, even 
though the differences in outcome could be explained by unforeseen bias. However, it is 
likely that HCT in CR1 for s-AML patients with intermediate and high-risk confers a true 
advantage in the same manner as for de novo AML.  
The comprehensive recent publications from EBMT, as referred to in the introduction, 
overshadow the results from study III regarding risk factors for outcome after HCT.  
Probably due to low number of patients in our study, only GvHD was significantly associated 
with outcome (mild chronic GvHD favorable, acute GvHD adverse). Owing to the EBMT 
reports, we now have strong data supporting not only the same GvHD findings [149], but also 
that MAC as opposed to RIC [155], related donor and BM as stem cell source [152] among 
other factors are beneficial for  OS. 
Nonetheless, the EBMT data on almost 5000 s-AML patients transplanted during 2000-2016 
show a 2-year OS rate of 44.5% [156], which is in line and comparable to the 37% 3-year 
survival of the patients in our study, in particular since the patients in study III were 
transplanted earlier in time (1997-2015). 
5.4 INCREASE IN T-AML INCIDENCE 
With an aging population and increasing incidence of cancer overall, together with advances 
in treatment and care of the patients, the prevalence of cancer survivors is rising and is 
expected to do so also in the future [173-175]. Thus, the population at risk of t-AML is 
enlarging and a possible explanation of the steady increase of incidence of t-AML seen in 
study IV.  However, the risk of t-AML following different cancers varies over time and is 
associated to changes in treatment protocols, which can be seen in comprehensive 
population-based U.S. data [71]. For instance, the risk of t-AML increased for non-Hodgkin 
lymphoma but decreased for myeloma and ovarian cancer during 1975-2008 [71]. 
Consequently, the prediction of the future incidence of t-AML is difficult. Moreover, 
incidence rates are highly dependent on age-structure, which makes crude comparisons with 
historical data across nations and time-periods difficult. Adjusting the data to an age 
distribution specific to a year or to a standard population, e.g. the world or European standard 
population, is one solution [176], but all data not coinciding with the reference will be 
skewed and may cause confusion.  
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5.5 FAVORABLE RISK T-AML 
Study IV suggested that t-AML confers no prognostic information in patients with favorable 
karyotype and in patients with the favorable NPM1+/FLT3-ITD- signature. However, no 
subgroup analysis was performed to investigate the relation to specific chromosomal 
aberrations and no extensive mutation profiling was available. Conversely, in a study 
comparing t-AML vs. de novo AML in patients with CBF-AML, t-AML had poorer survival 
after adjusting for age, performance status and other cytogenetic abnormalities [177]. Kayser 
and colleagues [6] found t-AML to be a negative prognostic factor in patients with inv(16) or 
t(16;16), but not significantly in t(15;17), t(8;21) or mutated NPM1, though only adjusted for 
WBC, not age or performance status. A likely explanation of the difference in outcome 
between the studies could be presence of adverse mutations coexisting in CBF-leukemia 
patients, e.g. mutations in KIT and chromatin modifiers and cohesin [178, 179]. A small 
study found that t-AML patients harboring t(8;21) had poorer OS than their de novo 
counterparts. However, the t-AML patients were older and no statistical adjustments were 
performed [180]. 
Furthermore, in a cohort of 305 s-AML patients, mutated NPM1 was an independent negative 
factor for prognosis adjusted for age, t-AML or AHD-AML, cytogenetic risk and FLT3-ITD 
status, however losing significance at age > 60 [181]. Moreover, only 72 patients had t-AML 
(of which only 3 were NPM1 mutated) and the other 233 MDS-AML (27 NPM1 mutated). 
Our cohort was t-AML only, which probably explains the discrepancy. On the other hand, the 
cytogenetic risk stratification used in our multivariable adjustment had NPM1 already 
included, which makes the statistical interpretation intricate. Furthermore, one can simply 
argue there is no proof that the NPM1 mutated t-AML patients in study IV truly are therapy-
related and not de novo, as NPM1 typically is associated with de novo and normal karyotype 
AML [182]. 
While study IV did not specifically focus on t-APL, OS was found to be similar in t-APL 
compared to de novo APL (poorer than de novo APL in crude analysis, but better after 
adjusting for age and performance status, both analyses non-significant however). Few large 
studies have compared t-APL and de novo APL, but most data support similar outcome in the 
two groups [183, 184], even though a higher rate of induction mortality in t-APL has been 
reported [185].  
Aldoss and Pullarkat nicely reviews favorable cytogenetic t-AML [186], and our data 
supports their conclusion that t-AML per se is no reason to intensify treatment or perform 
HCT in patients with favorable cytogenetics. 
5.6 CHANGES IN TREATMENT OVER TIME 
During the era in which the present studies took place, 1997-2015, very few new drugs for 
AML were approved. Practically all intensively treated patients received similar DA 
regimens. While hypomethylating agents were introduced in clinical practice in Sweden 
2008, only 142 patients (53 with AHD-AML, 61 with de novo, and 28 with t-AML) were 
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given HMAs as primary treatment until 2015 (unpublished data). HMAs are an option in 
patients not eligible for standard induction, and notably, only a handful actually reached CR 
according to the registry. The lack of new therapies introduced might seem gloom, however, 
as discussed in the introduction, new promising drugs are already underway. On the other 
hand, the standstill up to present has made the study of outcome in AML considerably 
simpler, since one of the most important variables has not changed over time. One can safely 
assume that a 40-year old Swede diagnosed in 2000 would get the same induction treatment 
if diagnosed 15 years later. In 2020, with the advent of new drugs, this is no longer certain. 
AML registries, including SAMLR, will have to be flexible enough to accommodate the 
multiple combinations of new treatment regimens, keep track of treatment periods and 
disease stages (not only remission/relapsed/refractory disease, but also relapse on MRD 
level). Altogether this will make coming clinical trials as well as observational studies highly 
complex with more and smaller subgroups of patients. 
5.7 LIMITATIONS 
Confounders and immortal-time bias 
The most problematic issue with analyses of survival and prognosis in the studies in this 
thesis was to control for confounders (e.g. to handle to interrelationships between the 
different risk factors). Confounding is a general problem in observational studies trying to 
estimate effects, and the multivariable models used to limit confounding are only models. No 
matter how meticulous you are in adjusting for covariates or how well you try to balance your 
groups of comparison, you can never eliminate bias completely in retrospective analyses.  
 
 
Figure 7. Illustration of immortal-time/guarantee-time bias. Survival from diagnosis 
(beginning of follow-up) appears longer in the transplantation group. However, in the 
transplantation group, patients are guaranteed to survive until date of transplantation, 
adding extra time to the transplantation group. Reprinted with permission from American 
Society of Clinical Oncology: Journal of Clinical Oncology, Challenges of Guarantee-Time 
Bias, A. Giobbie-Hurder et al, copyright 2013. 
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Guarantee-time bias or immortal time bias arises if two groups are compared and there is a 
period of time before a certain exposure when the event of outcome impossibly can occur in 
one of the groups [187] (Figure 7). This was a challenge in study III, where HCT was 
compared against CPRT and patients in the HCT-arm could not have experienced the event 
"death" between time zero and the time of the exposure "HCT". The patients in the CPRT-
arm, on the other hand, were at risk of death already from time zero. Crude analyses between 
the groups would result in a strong bias in favor for HCT, since patients that might have been 
candidates for HCT but died before the eventual transplantation all would be allocated to the 
CPRT-arm.  
In the comparison between HCT and CRPT in study III, several techniques were used to 
limit immortal time bias. First a landmark analysis in which follow-up started at day 200 and 
patients who died or relapsed before day 200 were excluded and the patients surviving to day 
200 were assigned either to the HCT arm if they had undergone HCT by day 200, or to the 
CPRT arm if not (robustness was checked by using 300 days as a landmark cutoff). Secondly, 
a multivariable Cox regression analysis with HCT as a time-varying covariate was 
performed. In addition, to reduce selection bias and balance confounding factors between 
groups, a propensity score matching analysis was performed, in which patients who 
underwent HCT were matched against patients who received CPRT with regards to age, 
cytogenetic risk, AML subtype and year of diagnosis. 
 
Limitations of registries 
The strengths of the Swedish acute myeloid leukemia registry are the truly population-based 
coverage, the large sample size and the rigorous follow-up. However, while the coverage 
compared to the population and to the national cancer register has been validated, there has 
been no thorough systematic validation of the overall data quality in SAMLR. There are 
missing data, e.g. incomplete karyotyping, which can make the interpretation and 
management of data a challenge. Data might be misclassified; either through recall bias or by 
simple input errors by the reporting clinicians, but also when retrospectively analyzing the 
data. Furthermore, there are changes over time that might cause bias. The overall study period 
spans almost 20 years, and reclassification of disease subtypes do occur (e.g. blast count 20% 
or 30% to separate AML from MDS). Furthermore, there might have been a change over time 
in the awareness of s-AML and to what extent clinicians have reported prior diseases and 
therapy. With this in mind, the results and conclusions in this thesis should continuously be 
evaluated and compared with independent studies from others. 
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6 CONCLUSIONS AND CLINICAL IMPLICATIONS 
• Mutational screening using targeted sequencing is a feasible method that adds 
prognostic information in addition to established risk-assessment tools in MDS and 
AML. Targeted sequencing of myeloid cancer genes has since the publication of 
study I been incorporated in the clinical routine for the diagnostic work-up of MDS 
and AML.  
 
• Patients with AML progressing from a prior hematologic disease or arising after 
chemo- or radiation therapy have lower remission rates and shorter overall survival 
than de novo AML. The negative impact of s-AML is independent of other risk 
factors, and while pronounced in younger patients, the  impact decreases in older 
patients. Thus, in clinical prognostic assessment, information about s-AML has less 
value in elderly patients.  
 
• Virtually no long-term survival can be seen in s-AML without HCT. The outcome 
without HCT is especially poor for AHD-AML and in particular MPN-AML. HCT 
should be considered for all s-AML patients who are otherwise eligeble for HCT.  
 
• The incidence of t-AML has increased steadily in Sweden during the last 20 years and 
the proportion t-AML of AML in total is becoming larger.  
 
• A large proportion of patients with t-AML have multiple prior cancers  and t-AML is 
commonly preceded by t-MDS. 
 
• The outcome of t-AML patients with favorable risk cytogenetics or a favorable 
mutational profile with mutated NPM1 in the absence of FLT3-ITD is similar to the 
outcome of patients with de novo AML with matching cytogenetic or mutational risk. 
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7 FUTURE PERSPECTIVES 
For such a detrimental disease as AML the word exciting might be a bit inappropriate. 
However, this is probably what many clinicians and researchers do feel about the current 
development in disease understanding and drug development. 
7.1 THE CHALLENGE OF INDIVIDUALIZED PROGNOSTICATION AND 
THERAPY 
The mapping of the genetic abnormalities, especially the mutational spectrum, the last few 
years has confirmed the molecular heterogeneity of AML. Large sequencing studies have 
been able to stratify prognosis based on both single somatic mutations and combinations of 
mutations. In addition, there is increased knowledge of the importance of the variant allele 
frequency of certain mutations (e.g. FLT3-ITD [188], TP53 [189]). Up until now, the 
cytogenetic aberrations and the somatic mutations making up the risk classification systems 
have been manageable knowledge for the individual clinician. However, due to the growing 
complexity of assessing genetic data, support from new computational prognostic tools might 
be required to aid clinical decision-making. These tools could not only use genetic data, but 
patient related and clinical factors as well. Proof-of-concept of knowledge banks to support 
individual prediction in this manner have already been developed, with a notable example of 
Gerstung and colleagues [190] who have made a predictive tool based on the sequencing 
1540 intensively treated patients publicly available. 
The abundance of potentially clinically relevant genetic subgroups is also a challenge when 
selecting therapy. One patient might have multiple drugable targets where it is not necessarily 
obvious which drug or combination of drugs to chose. Furthermore, since the current risk 
classification systems are based on outcome after standard intensive induction therapy, they 
will no longer be applicable if new effective drugs are introduced that change the outcome for 
certain subgroups. This highlights the importance of being able to dynamically update 
knowledge-banks and real-world registries to accommodate new and complex treatment 
protocols. 
Furthermore, there is a multitude of clinical trials investigating combinations of old and new 
drugs, with the aim of enabling "precision medicine" or personalized treatment. These trials 
involve subgroups of patients in different disease stages and with diverse clinical and 
molecular properties. As a result, the data and results generated will be highly complex to 
compare and evaluate. Models to manage trials combining interventions with observational 
real-world data in multi-institutional master protocols, using standardized reporting methods 
to databases storing clinical and molecular data along with outcomes have been suggested 
[191]. 
7.2 SCREENING FOR PRELEUKEMIC MUTATIONS? 
Since the combination of clonal hematopoiesis and cytotoxic therapy is a probable major 
factor in the pathogenesis of t-AML, the incentives should be strong to screen for high-risk 
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mutations in cancer patients about to start chemotherapy [97, 111], or to screen cancer 
patients post treatment as surveillance [192, 193]. Including inherited risk-alleles in these 
gene panels could also be of value to detect unnoticed syndromes at high risk for inherited 
AML [20]. However, to weigh the risk vs. benefit of adjusting chemotherapy regimens to 
prevent iatrogenic development of t-AML is obviously difficult and warrants more research. 
More controversial is the idea to monitor or screen for elevated risk of de novo AML in 
healthy individuals. Nonetheless, studies have shown that it is possible to risk-stratify clonal 
hematopoiesis, and that mutational signatures associated with increased risk of leukemia 
development can be detected several years before the onset of AML [112, 194]. The 
questions arising are many and complicated: Who should be monitored? What are the risks of 
over-diagnosis? Do we have any early interventions at hand?  
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